Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 222

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 222
---
 license agreement with Versitech Limited, the licensing entity of HKU, for ALS -4. Subsequently on June 7, 2018, the parties entered into a first amendment to the exclusive license agreement, and on July 10, 2019, the parties entered into a second amendment to the license agreement. On January 11, 2019, Acticule and Versitech Limited entered into a second license agreement for ALS -4, where Acticule exclusively licensed the intellectual property rights on certain HKU -ownedimprovements to the original licensed invention. Under the exclusive license agreements, we were granted an exclusive, royalty -bearing, sublicensable licenses to develop, make, have made, use, sell, offer for sale and import products that are covered by the licensed patents (as described below). The territory of the licenses is worldwide and the field of the licenses is for treatment or prevention of bacterial infections caused by Staphylococcus aureus including MRSA and bacterial virulence. We paid an upfront fee upon entering into the license agreements. We are required to pay less than 10% of the net sales of the licensed products sold by us or our affiliates as royalties, as well as a low teens percentage of sublicense royalties that we receive from our sublicensees, if any. In addition, we agreed to pay to the licensor aggregate regulatory milestones of up to US$1 million subject to the following achievements: submission of investigational new drug application; completion of phase1, 2 and 3 clinical trials; and submission of new drug application; grant of regulatory approval. We also agreed to pay to the licensor aggregate sales milestones of up to US$7.8 million subject to the following achievement: first commercial sale; and annual net sales exceeding US$100 million in one jurisdiction. Pursuant to the license agreements, Acticule became the exclusive licensee of 2 pending U.S. non -provisionalpatent applications and 2 PCT applications (now expired). Prior to the expiration of the PCT applications, we filed national phase applications in member states of the EPO, in PRC and 12 other jurisdictions. The claimed inventions are described as: “Compounds Affecting Pigment Production and Methods for Treatment of Bacterial Diseases.” Four (4) US patents and two (2) Israeli patents have been granted by the United States Patent and Trademark Office and the Israel Patent office respectively. Acticule has the right to grant sublicenses to third parties under the